Last Week in Biomedicine | May 23–29 | Part 1 of 2: BMS Myeloma, GSK Hep B Cure, Pfizer Lung Cancer
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Last Week in Biomedicine | May 23–29 | Part 1 of 2: BMS Myeloma, GSK Hep B Cure, Pfizer Lung Cancer
-
ナレーター：
-
著者：
In Part 1 we cover the three biggest clinical trial readouts from the week of May 23–29, 2026 — including two ASCO 2026 opening-day announcements that reshape oncology.
1. Bristol Myers Squibb — Mezigdomide for Relapsed or Refractory Multiple Myeloma (Phase 3)
2. GSK — Bepirovirsen for Chronic Hepatitis B Infection (Phase 3)
3. Pfizer — LORBRENA (lorlatinib) for ALK-Positive Non-Small-Cell Lung Cancer (Phase 3, 7-year update)
The biggest story: Bristol Myers Squibb's mezigdomide became the first Phase 3 win for the new CELMoD drug class, cutting disease progression risk in half for patients with relapsed or refractory multiple myeloma. The trial showed medianprogression-free survival of 18 months on mezigdomide combination versus 8.3 months on standard of care — a doubling of how long patients stay disease-stable.
Part 2 drops Thursday. Subscribe at TrialBreaks.com
#oncology #multiplemyeloma #lungcancer #hepatitisB #biomedicine #clinicaltrials#science #medicalresearch